BiotechTube

MRA(Tocilizumab)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Juvenile Idiopathic Arthritis

Conditions

Systemic Juvenile Idiopathic Arthritis

Trial Timeline

Jul 1, 2004 → Jun 1, 2009

NCT ID
NCT00144612

About MRA(Tocilizumab)

MRA(Tocilizumab) is a phase 3 stage product being developed by Chugai Pharmaceutical for Systemic Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144612. Target conditions include Systemic Juvenile Idiopathic Arthritis.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Juvenile Idiopathic Arthritis were approved

Approved (10) Terminated (4) Active (7)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅EfalizumabMerckApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00380601Phase 3Completed
NCT00144586Phase 3Completed
NCT00144625Phase 3Completed
NCT00144560Pre-clinicalCompleted
NCT00144573Pre-clinicalCompleted
NCT00144664Phase 3Completed
NCT00144612Phase 3Completed
NCT00144547Phase 3Completed
NCT00144651Phase 2Completed

Competing Products

20 competing products in Systemic Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40